Compare Cytokinetics Inc (CYTK) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $121.92 (market cap $1.45B). The key difference: Cytokinetics Inc is far larger — about 5.9× Direxion NASDAQ 100 Equal Weighted Index Shares's market cap, and Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Direxion NASDAQ 100 Equal Weighted Index Shares for 48 Days on average.
| CYTK | QQQE | |
|---|---|---|
Market Cap | $8.62B | $1.45B |
Volume | 2,594,626 | 323,568 |
Sector | Health | Broad Market / Factor |
52-Week High | $87.26 | $124.69 |
52-Week Low | $54.76 | $96.06 |
Typical Hold Time | 19 Days | 48 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.91, up 2.93% with bearish technical signals despite strong analyst support. The company shows promising drug development with positive Phase 3 results for aficamten in HCM treatment, though fundamentals remain challenged with a P/S ratio of 114 and negative profit margins. Recent executive stock sales and high cash burn from operations highlight ongoing financial pressures despite growing revenue potential from new drug launches.
The outlook balances significant upside potential from analyst price targets averaging $112.60 against substantial execution risks. While clinical successes position CYTK for growth in cardiovascular treatments, persistent losses and high valuation metrics require careful risk assessment. The stock offers speculative growth opportunity but demands close monitoring of commercialization progress and path to profitability.
QQQE trades at $121.92 with minimal daily movement (+0.02%). Technical indicators show a bullish trend with moving averages supporting upward momentum while oscillators remain neutral. The ETF's equal-weighted approach to NASDAQ-100 stocks provides diversification benefits, reducing technology concentration from 60% to 45% compared to market-cap weighted alternatives. Recent analysis suggests QQQE offers stronger fundamentals and technicals than QQQ for tactical positioning.
The outlook appears favorable with equal weighting providing balanced exposure to large-cap growth stocks. Key risks include technology sector volatility and market concentration concerns. Analyst sentiment leans positive for near-term performance, though investors should monitor broader market trends and sector rotations that could impact the NASDAQ-100 composition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
